Intelligent Bio Solutions Inc, a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced the successful receipt and deployment of the first shipment of Intelligent Fingerprinting Drug Screening Readers manufactured and shipped under its new strategic manufacturing partnership with Syrma Johari MedTech Ltd.
The shipment marks a significant step in scaling the company’s production capacity and validates the operational and financial benefits of the collaboration announced in December 2025.
The readers are now being deployed across key customer verticals, including construction, transportation and logistics, and manufacturing, throughout the UK and Europe, supporting growing commercial demand and expanding the Company's installed base ahead of planned entry into the US market, beyond the Forensic Use Only category, later this year.
The successful first reader shipment confirms that the Syrma Johari partnership is performing as planned, with readers meeting INBS' quality standards and manufactured in compliance with ISO 13485, MDSAP, and applicable regulatory requirements. With access to manufacturing capacity approximately four times its prior capability, the Company is now positioned to accelerate fulfillment and is on track to deliver annual production cost savings of more than 40%, translating to an expected improvement of approximately 20 percentage points in gross margin annually.
In addition to scaled reader production, INBS has considerably enhanced its manufacturing capabilities for the lateral flow test strip integral to its testing system. The Company has sourced advanced lateral flow manufacturing equipment that has doubled its in-house production capacity, delivering multiple strategic advantages including greater control over critical components that improve margins and reduce lead times, increased cartridge output that provides the product development team with expanded testing inventory for faster innovation cycles, and the ability to produce cartridges with additional test lines that unlock opportunities to explore expanded drug panels tailored to specific customer segments, regulatory markets, or emerging substance trends.
"Receiving and deploying our first shipment of readers from Syrma Johari, combined with doubling our in-house lateral flow test strip production capacity, is a transformational step in our ability to scale intelligently and profitably," said Callistus Sequeira, vice president of global quality & operations at Intelligent Bio Solutions. "We are building a vertically integrated, cost-efficient manufacturing engine that supports margin expansion, accelerates innovation, and positions us to enter the US market with operational strength and the capacity to grow with demand."
Successful delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned US market entry in 2026.
Partnership on track to deliver annual production cost savings of more than 40 per cent with expected improvement of approximately 20 percentage points in gross margin annually.
Doubled in-house lateral flow test strip production capacity strengthens vertical integration, accelerates R&D, and enables panel expansion. |